메뉴 건너뛰기




Volumn 549, Issue 7670, 2017, Pages 106-110

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Author keywords

[No Author keywords available]

Indexed keywords

CMTM4 PROTEIN; CMTM6 PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CMTM4 PROTEIN, HUMAN; MARVEL DOMAIN CONTAINING PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BINDING;

EID: 85029041186     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23669     Document Type: Article
Times cited : (508)

References (31)
  • 1
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , pp. 2443-2454
    • Topalian, S.L.1
  • 2
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1
  • 3
    • 84925221855 scopus 로고    scopus 로고
    • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
    • Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
    • (2015) N. Engl. J. Med. , vol.372 , pp. 311-319
    • Ansell, S.M.1
  • 4
    • 84923078390 scopus 로고    scopus 로고
    • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    • Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
    • (2014) Nature , vol.515 , pp. 558-562
    • Powles, T.1
  • 5
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
    • (2015) N. Engl. J. Med. , vol.372 , pp. 2018-2028
    • Garon, E.B.1
  • 6
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
    • (2015) N. Engl. J. Med. , vol.372 , pp. 2509-2520
    • Le, D.T.1
  • 7
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
    • (2015) N. Engl. J. Med. , vol.373 , pp. 1803-1813
    • Motzer, R.J.1
  • 8
    • 84976511909 scopus 로고    scopus 로고
    • PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
    • Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
    • (2016) N. Engl. J. Med. , vol.374 , pp. 2542-2552
    • Nghiem, P.T.1
  • 9
    • 84994812847 scopus 로고    scopus 로고
    • Nivolumab for recurrent squamous-cell carcinoma of the head and neck
    • Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
    • (2016) N. Engl. J. Med. , vol.375 , pp. 1856-1867
    • Ferris, R.L.1
  • 10
    • 31444451661 scopus 로고    scopus 로고
    • Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
    • Lee, S. J. et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett. 580, 755-762 (2006).
    • (2006) FEBS Lett. , vol.580 , pp. 755-762
    • Lee, S.J.1
  • 11
    • 84973131266 scopus 로고    scopus 로고
    • Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
    • Kataoka, K. et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
    • (2016) Nature , vol.534 , pp. 402-406
    • Kataoka, K.1
  • 12
    • 84960842480 scopus 로고    scopus 로고
    • MYC regulates the antitumor immune response through CD47 and PD-L1
    • Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
    • (2016) Science , vol.352 , pp. 227-231
    • Casey, S.C.1
  • 13
    • 84979502955 scopus 로고    scopus 로고
    • Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
    • Dorand, R. D. et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 (2016).
    • (2016) Science , vol.353 , pp. 399-403
    • Dorand, R.D.1
  • 14
    • 84984911573 scopus 로고    scopus 로고
    • Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
    • Li, C.-W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
    • (2016) Nat. Commun. , vol.7 , pp. 12632
    • Li, C.-W.1
  • 15
    • 85004025764 scopus 로고    scopus 로고
    • Deubiquitination and stabilization of PD-L1 by CSN5
    • Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925-939 (2016).
    • (2016) Cancer Cell , vol.30 , pp. 925-939
    • Lim, S.O.1
  • 16
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1
  • 17
    • 85008428512 scopus 로고    scopus 로고
    • What does PD-L1 positive or negative mean?
    • Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835-2840 (2016).
    • (2016) J. Exp. Med. , vol.213 , pp. 2835-2840
    • Ribas, A.1    Hu-Lieskovan, S.2
  • 18
    • 70849098603 scopus 로고    scopus 로고
    • Haploid genetic screens in human cells identify host factors used by pathogens
    • Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
    • (2009) Science , vol.326 , pp. 1231-1235
    • Carette, J.E.1
  • 19
    • 80052851832 scopus 로고    scopus 로고
    • Ebola virus entry requires the cholesterol transporter Niemann-Pick C1
    • Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
    • (2011) Nature , vol.477 , pp. 340-343
    • Carette, J.E.1
  • 20
    • 85020486879 scopus 로고    scopus 로고
    • Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling
    • Brockmann, M. et al. Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature 546, 307-311 (2017).
    • (2017) Nature , vol.546 , pp. 307-311
    • Brockmann, M.1
  • 21
    • 18844457095 scopus 로고    scopus 로고
    • Mechanisms of type-I- and type-II-interferon-mediated signalling
    • Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
    • (2005) Nat. Rev. Immunol. , vol.5 , pp. 375-386
    • Platanias, L.C.1
  • 22
    • 12444305419 scopus 로고    scopus 로고
    • Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation
    • Han, W. et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81, 609-617 (2003).
    • (2003) Genomics , vol.81 , pp. 609-617
    • Han, W.1
  • 23
    • 84930929328 scopus 로고    scopus 로고
    • Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis
    • Xiao, Y. et al. Identification of the common origins of osteoclasts, macrophages, and dendritic cells in human hematopoiesis. Stem Cell Rep. 4, 984-994 (2015).
    • (2015) Stem Cell Rep. , vol.4 , pp. 984-994
    • Xiao, Y.1
  • 24
    • 84882683958 scopus 로고    scopus 로고
    • The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3
    • Chen, Z. et al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity 39, 272-285 (2013).
    • (2013) Immunity , vol.39 , pp. 272-285
    • Chen, Z.1
  • 25
    • 84879703551 scopus 로고    scopus 로고
    • Strength of PD-1 signaling differentially afects T-cell effector functions
    • Wei, F. et al. Strength of PD-1 signaling differentially afects T-cell effector functions. Proc. Natl Acad. Sci. USA 110, E2480-E2489 (2013).
    • (2013) Proc. Natl Acad. Sci. USA , vol.110 , pp. E2480-E2489
    • Wei, F.1
  • 26
    • 84857400782 scopus 로고    scopus 로고
    • Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor
    • Miyazaki, A., Yogosawa, S., Murakami, A. & Kitamura, D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS ONE 7, e31829 (2012).
    • (2012) PLoS ONE , vol.7 , pp. e31829
    • Miyazaki, A.1    Yogosawa, S.2    Murakami, A.3    Kitamura, D.4
  • 27
    • 0001677717 scopus 로고
    • Controlling the False discovery rate: A practical and powerful approach to multiple testing
    • Benjamini, Y. & Hochberg, Y. Controlling the False discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
    • (1995) J. R. Stat. Soc. B , vol.57 , pp. 289-300
    • Benjamini, Y.1    Hochberg, Y.2
  • 28
    • 84940790892 scopus 로고    scopus 로고
    • Intra- and inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts
    • Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenibresistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104-1118 (2015).
    • (2015) EMBO Mol. Med. , vol.7 , pp. 1104-1118
    • Kemper, K.1
  • 29
    • 84950283765 scopus 로고    scopus 로고
    • A generic strategy for CRISPR-Cas9-mediated gene tagging
    • Lackner, D. H. et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat. Commun. 6, 10237 (2015).
    • (2015) Nat. Commun. , vol.6 , pp. 10237
    • Lackner, D.H.1
  • 30
    • 84957605863 scopus 로고    scopus 로고
    • Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
    • Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184-191 (2016).
    • (2016) Nat. Biotechnol. , vol.34 , pp. 184-191
    • Doench, J.G.1
  • 31
    • 36349004799 scopus 로고    scopus 로고
    • Selecting highly affine and well-expressed TCRs for gene therapy of melanoma
    • Jorritsma, A. et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 110, 3564-3572 (2007).
    • (2007) Blood , vol.110 , pp. 3564-3572
    • Jorritsma, A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.